Company Filing History:
Years Active: 2005
**Title: Innovator Jung Sik Lee: Advancements in Hemophilia A Treatment**
Introduction
Jung Sik Lee is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly concerning treatments for hemophilia A. His innovative work has led to the development of a specialized patent that enhances the stabilization of therapeutic preparations, paving the way for improved patient outcomes.
Latest Patents
Jung Sik Lee holds a patent for a pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer. This innovative preparation is crucial for treating hemophilia A. The patent details a method of lyophilization using a mixture that includes 6 to 100 mM of L-arginine, 3.5 to 50 mM of L-isoleucine, and 10 to 100 mM of L-glutamic acid. This approach stabilizes recombinant factor VIII, ensuring its effectiveness during the lyophilization process, while avoiding the use of human blood-derived albumin, which can raise safety concerns.
Career Highlights
Jung Sik Lee is currently employed at Korea Greencross Corporation, where he applies his expertise in biotechnology and pharmaceuticals. His role has allowed him to focus on innovative treatments that address critical health issues, particularly in the context of blood disorders like hemophilia.
Collaborations
Throughout his career, Jung Sik Lee has collaborated with fellow researchers and innovators, including Sang Hoon Paik and Yong Nam Shin. These partnerships enhance the development and refinement of pharmaceutical products, illustrating the importance of teamwork in advancing medical science and technology.
Conclusion
Jung Sik Lee's inventive efforts in creating a novel lyophilized preparation of recombinant factor VIII highlight his commitment to improving therapies for hemophilia A. His progressive work at Korea Greencross Corporation, coupled with valuable collaborations, positions him as a significant figure in the field of pharmaceutical innovation. The impact of his patent is expected to resonate positively within the medical community, offering hope for better management of hemophilia A.